UROGEN PHARMA LTD (URGN) Stock Income Statement
NASDAQ:URGN - Nasdaq - IL0011407140 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 91.87M | 90.40M | 82.71M | 64.36M | 48.04M | |||
| Cost Of Goods | 9.48M | 8.88M | 9.36M | 7.65M | 5.16M | |||
| Gross Profit | 82.39M | 81.52M | 73.35M | 56.70M | 42.89M | |||
| Operating Expenses | 190.34M | 178.30M | 138.89M | 135.75M | 135.17M | |||
| Research and Development | 61.52M | 57.15M | 45.61M | 52.91M | 47.64M | |||
| Selling, General, and Administrative Expenses | 128.82M | 121.15M | 93.27M | 82.84M | 87.54M | |||
| Operating Income | -107.96M | -96.78M | -65.54M | -79.04M | -92.29M | |||
| Interest Income/Expense | -4.65M | -3.62M | -12.07M | -7.50M | 370.00K | |||
| Other Income/Expense | -22.66M | -23.64M | -20.71M | -21.49M | -17.44M | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -135.26M | -124.04M | -98.32M | -108.03M | -109.37M | |||
| Income Tax | 3.17M | 2.83M | 3.92M | 1.76M | 1.45M | |||
| Net Income | -138.43M | -126.87M | -102.24M | -109.78M | -110.82M | |||
| EBITDA | -107.25M | -96.45M | -64.73M | -78.12M | -91.46M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.03 | -2.96 | -3.55 | -4.81 | -4.96 | |||
| Non GAAP EPS | -3.18 | -3.23 | -3.73 | -4.78 | -4.96 | |||
| Statistics | ||||||||
| Gross Profit Margin | 89.68% | 90.18% | 88.68% | 88.10% | 89.28% | |||
| Profit Margin | -150.68% | -140.35% | -123.61% | -170.57% | -230.68% | |||
| Operating Profit Margin | -117.51% | -107.06% | -79.23% | -122.81% | -192.11% | |||
All data in USD